<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="should be referred to a COVID-19 designated clinic for further" exact="testing" post="if indicated.[3] Eyes could act as a portal of"/>
 <result pre="may also transmit the virus in the community. Currently, the" exact="treatment" post="for symptomatic COVID-19 infection is mainly supportive, and the"/>
 <result pre="virus in the community. Currently, the treatment for symptomatic COVID-19" exact="infection" post="is mainly supportive, and the medical fraternity is still"/>
 <result pre="COVID-19 conjunctivitis and not let these cases go away without" exact="treatment" post="like any other viral conjunctivitis. Even though all COVID-19"/>
 <result pre="to 0.04%. BAK was found to be effective in the" exact="treatment" post="of adenoviral conjunctivitis in a few studies. It is"/>
 <result pre="are the only drugs currently recommended for the prophylaxis and" exact="treatment" post="of COVID-19-related disease. In a small study on patients"/>
 <result pre="load. 0.03% chloroquine eye drops have been used for the" exact="treatment" post="of dry eye disease in a few studies.[7] This"/>
 <result pre="5PeposeJSAhujaALiuWNarvekarAHaqueRRandomized, controlled, phase 2 trial of Povidone-Iodine/dexamethasone ophthalmic suspension for" exact="treatment" post="of adenoviral conjunctivitisAm J Ophthalmol201819471529787732 6RamalingamSCaiBWongJTwomeyMChenRFuRMet al.Antiviral innate immune"/>
</results>
